COPENHAGEN (dpa-AFX) - Denmark's Genmab A/S (GMAB) is in advanced negotiations to acquire Merus NV (MRUS), a Dutch biopharmaceutical company developing treatments for head and neck cancer, Bloomberg reported citing people familiar with the matter.
Merus, listed on Nasdaq with a market capitalization of approximately $5.1 billion, has attracted takeover interest from several major pharmaceutical firms in recent weeks and may announce a deal within days, the report said.
If completed, the acquisition would mark the largest in Genmab's history.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
